Drug intelligence / Profile preview

Y13

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intraperitoneal

Overview

Y13 is a monoclonal antibody that targets Ha-Ras. In the provided context, it was utilized as a control antibody in preclinical murine melanoma studies. Its purpose was to serve as a baseline for comparison against the active treatment, which involved the anti-CD25 monoclonal antibody PC61 in combination with dendritic cell-tumor fusion vaccines.

Other names: anti-HaRas

Targets

HRAS (H-Ras protein)

Beyond the preview

Go deeper on Y13.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Y13.

Explore the full profile